Catalent is continuing to expand its fast-growing biologics operations, agreeing to acquire Bristol-Myers Squibb (BMS)’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, for an undisclosed price.
SUBSCRIBE
Biohealth Innovation
Founding Member of
